DPL Responds to CMS Proposed Changes to OPPS Policy
The Drug Pricing Lab submits commentary on the proposed changes to Center for Medicare and Medicaid Services (CMS) Program Hospital Outpatient Prospective Payment (OPPS) policy regarding payment for drugs and biologic drugs purchased with a 340B program discount. Details of proposed rule CMS-1678-P are found here.
Drug Pricing Lab Report, Hospital outpatient versus physician office cost for physician administered cancer drugs, (Jan 2017).
Conti RM, Bach PB. Cost Consequences of the 340B Drug Discount Program. JAMA : the journal of the American Medical Association. 2013;309(19):1995-1996. doi:10.1001/jama.2013.4156.
See GAO, Rep. No. GAO-15-442, Medicare Part B Drugs: Action Needed to Reduce Financial Incentives to Prescribe 340B Drugs at Participating Hospitals, 20 (June 2015).
H.R. Rep. No. 108-391, at 582-83 (Nov. 2003).